title: Questions we should be asking about bevacizumab for cervical cancer.
authors.forename: Lynette A
authors.initials: LA
authors.lastname: Denny
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics / Q000627:therapeutic use*; D000068258:Bevacizumab; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000401:mortality
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab